BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27626779)

  • 1. Targeted therapy: An elusive cancer target.
    Brown C
    Nature; 2016 Sep; 537(7620):S106-8. PubMed ID: 27626779
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspective: What next for treatment?
    Motzer RJ
    Nature; 2016 Sep; 537(7620):S111. PubMed ID: 27626781
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
    Gao X; McDermott DF; Michaelson MD
    Oncologist; 2019 Jun; 24(6):725-727. PubMed ID: 31036769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
    Abrahamson PA
    Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
    [No Abstract]   [Full Text] [Related]  

  • 5. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 6. [Renal cell carcinoma: the end of a tunnel?].
    Ravaud A; Dilhuydy MS
    Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
    [No Abstract]   [Full Text] [Related]  

  • 7. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeted therapy for renal cell carcinoma].
    Terai K; Horie S
    Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.
    Porta C; Szczylik C; Escudier B
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):323-37. PubMed ID: 21733715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What advances have been made in immune-therapy for renal cell carcinoma?
    Verzoni E; Grassi P; Ratta R
    Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I
    Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to overcome therapeutic resistance in renal cell carcinoma.
    Siska PJ; Beckermann KE; Rathmell WK; Haake SM
    Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for kidney cancer in urologic practice.
    Haas NB; Uzzo RG
    Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for renal cell cancer: what are possible options?
    Santos N; Wenger JB; Havre P; Liu Y; Dagan R; Imanirad I; Ivey AM; Zlotecki RA; Algood CB; Gilbert SM; Allegra CJ; Okunieff P; Vieweg J; Dang NH; Luesch H; Dang LH
    Oncology; 2011; 81(3-4):220-9. PubMed ID: 22085914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.